B2B only. For licensed importers and distributors. Tender authorities and healthcare institutions are also served. Not for retail or patient supply.  ·  Compliance statement
Home/Insights/Product comparison
Product comparison

Rabies immunoglobulin vs rabies vaccine: what's the difference

Both are used in post-exposure rabies care, and both move on the same cold chain. But one is a ready-made antibody preparation and the other is a vaccine that builds immunity over a series of doses — and that difference decides what a procurement programme must include.

Two immune products, one disease, and a persistent procurement confusion: treating rabies immunoglobulin (RIG) and rabies vaccine as if they were two strengths of the same post-exposure product. They are not. A buyer who merges the two lines, or who treats them as interchangeable, has bought a programme that does not match the exposure profile the public-health framework requires.

This comparison is written for licensed importers, distributors and tender authorities — the people who have to assemble a complete post-exposure prophylaxis (PEP) programme, with the right product on the right line and the paperwork to prove it. It describes what each product is and how they differ, and ends with a decision guide for the procurement side.

The one-sentence difference

The rabies vaccine is an active immunisation — it prompts the recipient's own immune system to build antibodies over a scheduled series of doses. Rabies immunoglobulin is a passive immunisation — a ready-made preparation of rabies antibodies given for immediate protection in the days before the vaccine takes effect. The vaccine builds immunity; the immunoglobulin buys time.

Side-by-side comparison

Dimension Rabies immunoglobulin Rabies vaccine (Vero cell)
What it is Ready-made rabies antibodies (passive immunisation) Freeze-dried vaccine that builds active immunity
Role in PEP Immediate, short-term protection after exposure Longer-term immunity over a scheduled series
Presentation 200 IU / 2 ml solution 0.5 ml per dose · 5-dose and 4-dose regimens
Dosage form Solution for injection Lyophilised powder with solvent
Storage 2–8 °C, protected from light 2–8 °C, protected from light
Shelf life 36 months 30 months
Approval number NMPA S20053040 NMPA S20250069
Manufacturer China Resources Boya Guangzhou Baiyunshan Bioproducts

The approval numbers make the point in a single line: rabies immunoglobulin and rabies vaccine carry different 国药准字 numbers because they are different registered products, made by different manufacturers. A quotation that presents one number against the other product's line is a mismatch, not a substitution.

Why the difference matters at procurement

The distinction is not academic, and it shows up in three places the buying side has to get right.

Separate tender lines

Rabies immunoglobulin and rabies vaccine are specified for different functions within a PEP programme, so they appear as separate lines in a tender and in national immunisation and essential-medicine frameworks. They are complementary, not interchangeable, and a programme that omits one is incomplete for certain exposure profiles.

Separate registration dossiers

Each product holds its own registration certificate, its own batch release pathway, and — unlike most pairs on this site — a different manufacturer. The dossier that registers the immunoglobulin does not register the vaccine, and the import licence in the destination market names the specific product and manufacturer.

Same logistics, different manufacturers

Both move at 2–8 °C, protected from light, so a single validated cold chain can serve both. But the batch release certificate, certificate of analysis and approval reference are product-specific, and the two products originate from different manufacturers, so the supplier file must name each source correctly.

How to decide what your programme needs

The decision belongs to the exposure profile the programme is designed to cover, not to the buyer's preference. The question that resolves it is whether the programme must address post-exposure care, pre-exposure prophylaxis, or both.

  • If the programme covers post-exposure care for high-risk exposures, it generally needs both — the immunoglobulin for immediate protection and the vaccine for the scheduled series.
  • If the requirement names only active immunisation, the line is rabies vaccine.
  • If the requirement names immediate post-exposure protection, the line is rabies immunoglobulin.
  • If the requirement is ambiguous, stop and ask for the exposure profile before quoting — the two products are not alternatives, and guessing is how an incomplete programme is assembled.

Where the two genuinely do overlap is on the channel side: both products are supplied under the same export mandate, so a single supplier file can cover both lines even though they originate from different manufacturers.

Frequently asked questions

Are rabies immunoglobulin and rabies vaccine the same thing?

No. Rabies vaccine triggers the body to produce its own antibodies over a series of doses, while rabies immunoglobulin is a ready-made preparation of antibodies given for immediate, short-term protection after exposure. They do different jobs and are used together, not interchangeably.

Does a procurement brief need both products?

It depends on the exposure profile the buying programme is designed for. A full post-exposure prophylaxis programme typically needs both, because they are complementary rather than alternative. The two are separate tender lines and should be specified separately.

Do the two products need the same cold chain?

Yes, both are shipped and stored at 2–8 °C protected from light. The rabies vaccine is lyophilised with solvent, while the rabies immunoglobulin is a ready-to-use solution, but both share the same 2–8 °C cold-chain requirement.

What presentations are available?

The rabies immunoglobulin is supplied at 200 IU in 2 ml single-dose vials. The rabies vaccine (Vero cell) is supplied as a freeze-dried powder with solvent at 0.5 ml per dose, in 5-dose and 4-dose regimens.

Are they made by the same manufacturer?

No. The rabies immunoglobulin is supplied by China Resources Boya, while the Vero cell rabies vaccine is supplied by Guangzhou Baiyunshan Bioproducts. Both are supplied under wanyoda's export mandate through a single export channel.

Where to go next

Sourcing

Specify the right product on the right line.

Tell us the exposure profile and destination market, and we will confirm the matching product, approval reference and registration dossier.